Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

06.08.2022 - Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment ...

Related Keywords

United Kingdom ,California ,United States ,San Francisco ,Ukraine ,American ,Reprod Genet ,Uneek Mehra ,James Rusnak ,Linda Giudice ,Arjona Ferreira ,University Of California ,Linkedin ,Twitter ,Adamson ,Pfizer ,Sumitomo Pharma Co Ltd ,Facebook ,Program Steering Committee ,Myovant Sciences Forward ,Effect On Other Laboratory ,American Society For Reproductive Medicine ,Myovant Sciences ,European Commission ,Drug Administration ,Women Health ,Global Product Development ,Exchange Commission ,Myovant Sciences Contacts ,Youtube ,Corporate Communications ,Myovant Sciences Inc ,Healthcare Products Regulatory Agency ,Sumitovant Biopharma Ltd ,Senior Vice ,Chief Development Officer ,Internal Medicine ,Distinguished Professor ,Boxed Warning ,Sensitive Malignancies ,Mood Disorders ,Including Depression ,Transaminase Elevations ,Cholestatic Jaundice ,Blood Pressure ,Menstrual Bleeding Pattern ,Reduced Ability ,Recognize Pregnancy ,Early Pregnancy Loss ,Fibroid Prolapse ,Lipid Metabolism ,P Gp Inhibitors ,United Kingdom Medicines ,New Drug Application ,United States Prescribing Information ,Sumitovant Biopharma ,Breakthroughs That Change Patient ,Private Securities Litigation Reform Act ,Myovant Science ,United States Securities ,Quarterly Report ,Annual Report ,Looking Information ,Factors That May Affect Future ,Reproductive Medicine ,Human Reproduction ,Best Pract Res Clin Obstet ,Gynecol Obstet ,